Credit data is a valuable source of information for life insurers, as it can reveal insights into the financial behavior and stability of applicants. But how does credit data interact with other types of data, such as prescription drug and medical billing data, to predict mortality risk?
In a new white paper, 69É«ÇéƬ experts Mark Ma, Guizhou Hu, and Taylor Pickett present the results of their actuarial validation of Milliman Irix® – Risk Score 3.0 with Credit, a commercial risk-scoring product that combines prescription drug, medical billing, and credit data to generate four different scores for mortality risk segmentation.
The study compared the performance of the four models and scores, namely Rx3.0, RxDx3.0, RxCr3.0, and RxDxCr3.0, and found that:
Read the white paper for a comprehensive analysis of the Milliman Irix - Risk Score 3.0 with Credit, and to find out how credit data can enhance mortality risk prediction.
At 69É«ÇéƬ, we are eager to engage with clients to better understand and tackle the industry’s most pressing challenges together. Contact us to discuss and to learn more about 69É«ÇéƬ's capabilities, resources, and solutions.
